{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-102874","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.831314+00:00","generated_at":"2026-06-17T01:23:40.369614+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vaxcyte reports positive Phase 2 data for VAX-24 in adults 65+; met key immunogenicity criteria vs Prevnar 20","bullets":["VAX-24 2.2mcg dose met OPA non-inferiority for 18 of 20 serotypes common with Prevnar 20 and superiority for all four unique serotypes.","Robust immune responses across all 24 serotypes at all doses in adults 65+, confirming prior Phase 2 results in adults 50-64.","Full six-month safety data from both adult studies showed VAX-24 safety and tolerability similar to PCV20 with no related serious adverse events.","Prespecified pooled analyses (age 50+ and 60+) showed VAX-24 2.2mcg met OPA non-inferiority for all 20 common serotypes and superiority for four unique.","Company plans End-of-Phase 2 meeting with FDA in H2 2023; topline Phase 3 data in adults expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-102874","json":"https://secwatch.observer/filing/0001193125-23-102874.json","markdown":"https://secwatch.observer/filing/0001193125-23-102874.md","text":"https://secwatch.observer/filing/0001193125-23-102874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523102874/0001193125-23-102874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523102874/d492750d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:23:40.369614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}